Cite
HARVARD Citation
Wei, L. et al. (n.d.). A phase 3, open‐label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. Journal of gastroenterology and hepatology. 31 (11), pp. 1860-1867. [Online].